All Relations between Dyskinesias and serotonin

Publication Sentence Publish Date Extraction Date Species
Rossella Cirillo, Sandra Duperrier, Pathik Parekh, Mathilde Millot, Qin Li, Marie-Laure Thiolat, Micaela Morelli, Jing Xie, Didier Le Bars, Jérôme Redouté, Erwan Bezard, Véronique Sgambat. Striatal Serotonin 4 Receptor is Increased in Experimental Parkinsonism and Dyskinesia. Journal of Parkinson's disease. 2024-02-10. PMID:38339940. striatal serotonin 4 receptor is increased in experimental parkinsonism and dyskinesia. 2024-02-10 2024-02-12 rat
Sakiko Hirofuji, Koumi Miyasaka, Mika Maezawa, Wataru Wakabayashi, Keita Oura, Satoshi Nakao, Nanaka Ichihara, Yuka Nokura, Moe Yamashita, Kensuke Matsui, Hideyuki Tanaka, Mayuko Masuta, Ichiro Ieiri, Kazuhiro Iguchi, Mitsuhiro Nakamur. Evaluation of neuroleptic malignant syndrome induced by antipsychotic drugs using spontaneous reporting system. Heliyon. vol 9. issue 11. 2023-11-30. PMID:38034668. cluster 2 consisted of all aaps alongside several taps, such as haloperidol and chlorpromazine, with higher reporting rates of disturbance of consciousness, extrapyramidal disorders (excluding dyskinesia and dystonia), and serotonin syndrome. 2023-11-30 2023-12-10 Not clear
Sarah Chaib, Benjamin Vidal, Caroline Bouillot, Ronan Depoortere, Adrian Newman-Tancredi, Luc Zimmer, Elise Levigoureu. Multimodal imaging study of the 5-HT NeuroImage. Clinical. vol 39. 2023-08-26. PMID:37632990. multimodal imaging study of the 5-ht the leading treatment for motor signs of parkinson's disease is l-dopa, but, upon extended use, it can lead to levodopa-induced dyskinesia (lid). 2023-08-26 2023-09-07 Not clear
Mikael Thomsen, Anca Stoica, Kenneth Vielsted Christensen, Tue Fryland, Jens D Mikkelsen, John Bondo Hanse. Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats. Experimental neurology. 2022-08-21. PMID:35988699. synergistic effect of serotonin 1a and serotonin 1b/d receptor agonists in the treatment of l-dopa-induced dyskinesia in 6-hydroxydopamine-lesioned rats. 2022-08-21 2023-08-14 rat
Sophie R Cohen, Michelle L Terry, Michael Coyle, Emily Wheelis, Ashley Centner, Samantha Smith, John Glinski, Natalie Lipari, Carla Budrow, Fredric P Manfredsson, Christopher Bisho. The multimodal serotonin compound Vilazodone alone, but not combined with the glutamate antagonist Amantadine, reduces l-DOPA-induced dyskinesia in hemiparkinsonian rats. Pharmacology, biochemistry, and behavior. 2022-05-05. PMID:35513119. the multimodal serotonin compound vilazodone alone, but not combined with the glutamate antagonist amantadine, reduces l-dopa-induced dyskinesia in hemiparkinsonian rats. 2022-05-05 2023-08-13 rat
Xiao-Zhong Jing, Xiang-Zhen Yuan, Xingguang Luo, Shu-Yun Zhang, Xiao-Ping Wan. An Update on Nondopaminergic Treatments for Motor and Non-motor symptoms of Parkinson's disease. Current neuropharmacology. 2022-02-23. PMID:35193486. sustained-release agents of amantadine were approved for treating levodopa induced dyskinesia (lid), and serotonin 5ht1b receptor agonist also showed clinical benefits to lid. 2022-02-23 2023-08-13 human
Cynthia Kwan, Catherine Lévesque, Dominique Bédard, Imane Frouni, Jemal M Yesuf, Adjia Hamadjida, Daniel Lévesque, Paul Bs Clarke, Philippe Huo. Autoradiographic labelling of 5-HT Neuroscience research. 2021-12-26. PMID:34954302. autoradiographic labelling of 5-ht l-3,4-dihydroxyphenylalanine (l-dopa) is the mainstay treatment for parkinson's disease, but its effectiveness during early disease is marred by the eventual development of l-dopa induced dyskinesia. 2021-12-26 2023-08-13 rat
Xinxin Jiang, Peirong Liang, Ke Wang, Jun Jia, Xiaomin Wan. Serotonin 1A receptor agonist modulation of motor deficits and cortical oscillations by NMDA receptor interaction in parkinsonian rats. Neuropharmacology. vol 203. 2021-12-03. PMID:34785162. although serotonin 1a (5-ht1a) receptor agonists are widely used as the additive compound to reduce l-dopa-induced dyskinesia in parkinson's disease (pd), few studies focused on the effect and mechanism of 5-ht1a receptor agonist on the motor symptoms of pd. 2021-12-03 2023-08-13 rat
Feras Altwal, Fernando E Padovan-Neto, Alexandra Ritger, Heinz Steiner, Anthony R Wes. Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson's Disease. Molecules (Basel, Switzerland). vol 26. issue 19. 2021-11-16. PMID:34641332. research has identified abnormal dopamine release from serotonergic (5-ht) terminals contributing to this dyskinesia. 2021-11-16 2023-08-13 Not clear
Emma L Lane, David J Harrison, Elena Ramos-Varas, Rachel Hills, Sophie Turner, Mariah J Lelo. Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2021-11-12. PMID:34766658. spontaneous graft-induced dyskinesias are independent of 5-ht neurons and levodopa priming in a model of parkinson's disease. 2021-11-12 2023-08-13 Not clear
Emma L Lane, David J Harrison, Elena Ramos-Varas, Rachel Hills, Sophie Turner, Mariah J Lelo. Spontaneous Graft-Induced Dyskinesias Are Independent of 5-HT Neurons and Levodopa Priming in a Model of Parkinson's Disease. Movement disorders : official journal of the Movement Disorder Society. 2021-11-12. PMID:34766658. current theories implicate the presence of grafted serotonin neurons, hotspots of dopamine release, neuroinflammation and established levodopa-induced dyskinesia. 2021-11-12 2023-08-13 Not clear
Véronique Sgambat. Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine. Progress in brain research. vol 261. 2021-10-22. PMID:33785131. the lesion of 5-ht fibers induced by mdma altered rigidity and prevented dyskinesia and neuropsychiatric-like symptoms induced by levodopa therapy in mptp-treated animals. 2021-10-22 2023-08-13 monkey
Sara Corsi, Roberto Stancampiano, Manolo Cart. Serotonin/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update. Progress in brain research. vol 261. 2021-10-22. PMID:33785132. in this review, we focus on the interplay between dopamine and serotonin in the appearance of l-dopa-induced dyskinesia (lid), the most troublesome side effect of l-dopa therapy. 2021-10-22 2023-08-13 Not clear
R Depoortere, T H Johnston, S H Fox, J M Brotchie, A Newman-Tancred. The selective 5-HT Parkinsonism & related disorders. vol 78. 2021-10-04. PMID:32846366. the selective 5-ht long-term treatment of parkinson's disease (pd) with l-dopa typically leads to development of l-dopa induced dyskinesia (lid). 2021-10-04 2023-08-13 Not clear
Annalisa Pinna, Giulia Costa, Marcello Serra, Liliana Contu, Micaela Morell. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT Neuropharmacology. vol 196. 2021-10-01. PMID:34229013. neuroinflammation and l-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of parkinson's disease are counteracted by combined administration of a 5-ht several lines of evidence have strongly implicated neuroinflammation in parkinson's disease (pd) progression and l-dopa-induced dyskinesia. 2021-10-01 2023-08-13 rat
Cynthia Kwan, Stephen G Nuara, Dominique Bédard, Fleur Gaudette, Jim C Gourdon, Francis Beaudry, Philippe Huo. Selective blockade of the 5-HT Neuropharmacology. vol 182. 2021-09-24. PMID:33152452. selective blockade of the 5-ht in parkinson's disease (pd), management of l-3,4-dihydroxyphenylalanine (l-dopa)-related complications, such as l-dopa induced dyskinesia and psychosis, remains inadequate, which poses a significant burden on the quality of life of patients. 2021-09-24 2023-08-13 rat
Sergio Vegas-Suárez, Asier Aristieta, Catalina Requejo, Harkaitz Bengoetxea, José Vicente Lafuente, Cristina Miguelez, Luisa Uged. The effect of 5-HT British journal of pharmacology. vol 178. issue 12. 2021-07-05. PMID:33686657. the effect of 5-ht l-dopa prolonged treatment leads to disabling motor complications as dyskinesia that could be decreased by drugs acting on 5-ht 2021-07-05 2023-08-13 Not clear
Feras Altwal, Connor Moon, Anthony R West, Heinz Steine. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells. vol 9. issue 10. 2021-07-02. PMID:33050305. such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from serotonin terminals. 2021-07-02 2023-08-13 rat
Feras Altwal, Connor Moon, Anthony R West, Heinz Steine. The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson's Disease. Cells. vol 9. issue 10. 2021-07-02. PMID:33050305. previous work showed that modulating the striatal serotonin innervation with selective serotonin reuptake inhibitors (ssris) or 5-ht1a receptor agonists could attenuate l-dopa-induced dyskinesia. 2021-07-02 2023-08-13 rat
Cynthia Kwan, Imane Frouni, Dominique Bédard, Adjia Hamadjida, Philippe Huo. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. Behavioural pharmacology. vol 32. issue 1. 2021-06-21. PMID:33399295. we have previously demonstrated that serotonin type 3 (5-ht3) receptor blockade with the clinically available and highly selective antagonist ondansetron alleviates dyskinesia in the 6-hydroxydopamine (6-ohda)-lesioned rat. 2021-06-21 2023-08-13 rat